In particular, an ERCC1-XPF endonuclease inhibitor (IC50 < 1 μM), with specificity against another endonuclease and, despite only showing  ̃2-fold enhanced sensitivity to cisplatin, potentiated cisplatin activity in a lung cancer xenograft model [44]. This evidence concerns the gene ERCC4 and lung cancer.